Patents by Inventor Kate Sasser

Kate Sasser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR USE IN THERAPY
    Publication number: 20230087164
    Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.
    Type: Application
    Filed: February 4, 2021
    Publication date: March 23, 2023
    Inventors: Ugur SAHIN, Alexander MUIK, Isil ALTINTAS, Ulf FORSSMANN, Kate SASSER, Maria JURE-KUNKEL, Manish GUPTA
  • IBRUTINIB COMBINATION THERAPY
    Publication number: 20200368235
    Abstract: Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and second anticancer agents.
    Type: Application
    Filed: August 1, 2019
    Publication date: November 26, 2020
    Inventors: Betty Chang, Sriram Balasubramanian, Richard Crowley, Hsu-Ping Kuo, Brett Hall, Kate A. Sasser, Tineke Casneuf, Michael Schaffer, Matthias Versele, Willem Ligtenberg, Cue Davis
  • Blocking CD38 using anti-CD38 F(ab?)2 to protect NK cells
    Patent number: 10106620
    Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 23, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Janssen Biotech, Inc.
    Inventors: Richard W. Childs, Maria Berg, Luis Espinoza Calderon, Kate Sasser, Ricardo Attar
  • BLOCKING CD38 USING ANTI-CD38 F(ab')2 TO PROTECT NK CELLS
    Publication number: 20180208669
    Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.
    Type: Application
    Filed: June 15, 2015
    Publication date: July 26, 2018
    Applicants: The United States of America, as represented by th e Secretary, Dept. of Health and Human Services, Janssen Biotech, Inc.
    Inventors: Richard W. Childs, Maria Berg, Luis Espinoza Calderon, Kate Sasser, Ricardo Attar
  • IBRUTINIB COMBINATION THERAPY
    Publication number: 20160287592
    Abstract: Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and second anticancer agents.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 6, 2016
    Inventors: Betty CHANG, Sriram BALASUBRAMANIAN, Richard CROWLEY, Hsu-Ping KUO, Brett HALL, Kate A. SASSER, Tineke CASNEUF, Michael SHAFFER, Matthias VERSELE, Willem LIGTENBERG, Cuc DAVIS